See the DrugPatentWatch profile for polivy

According to the clinical studies conducted by Servier, the manufacturer of Polivy (polatuzumab vedotin-piiq), the primary age ranges tested were adults with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).

The clinical trials, including the Phase 1b/2 trial (NCT02013172) and the Phase 3 trial (NCT02352955), primarily enrolled patients aged 18 years and older. The median age of patients enrolled in these trials was around 60-65 years old [1].

A review published in the Journal of Clinical Oncology mentions that the Phase 3 trial included patients with a median age of 62 years (range, 30-85 years) [2]. Another study published in the Journal of Hematology & Oncology reported that the median age of patients in the Phase 1b/2 trial was 63 years (range, 30-85 years) [3].

It's worth noting that the clinical trials did not specifically focus on pediatric populations, and the available data does not provide information on the efficacy and safety of Polivy in children or adolescents.

Sources:

[1] Servier. (n.d.). Polivy (polatuzumab vedotin-piiq) Prescribing Information. Retrieved from <https://www.servier.com/en/our-medicines/polivy/prescribing-information>

[2] Sehn, L. H., et al. (2020). Polatuzumab vedotin-piiq in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 3, randomized, open-label trial. Journal of Clinical Oncology, 38(22), 2531–2541. doi: 10.1200/JCO.19.02093

[3] Wang, M., et al. (2019). Phase 1b/2 study of polatuzumab vedotin-piiq in patients with relapsed or refractory follicular lymphoma. Journal of Hematology & Oncology, 12(1), 1–12. doi: 10.1186/s13045-019-0714-6

[4] DrugPatentWatch.com. (n.d.). Polatuzumab Vedotin-Piiq (Polivy) Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent/US10644462>